Biogen and Envisagenics Enter into a Collaboration for the Advancement of RNA Splicing Research to Treat Central Nervous System Diseases

 Biogen and Envisagenics Enter into a Collaboration for the Advancement of RNA Splicing Research to Treat Central Nervous System Diseases

Shots:

  • Biogen will utilize Envisagenics’ SpliceCore, an AI- driven RNA splicing platform to understand the regulation of different RNA isoforms in CNS cell types which will provide access to SpliceCore’s database of ~7M RNA splicing errors
  • The collaboration will identify and validate disease genetic targets to increase the success rate in the CNS drug discovery
  • The addition of Envisagenics’ machine learning algorithms and high-performance computing helps to identify, test, and validate splicing errors at a large scale

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Biogen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post